Clinical Trials Logo

Neoplasm, Residual clinical trials

View clinical trials related to Neoplasm, Residual.

Filter by:

NCT ID: NCT00795756 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Intrathecal DepoCyte and Lineage-targeted Minimal Residual Disease-oriented Therapy of Acute Lymphoblastic Leukemia

Start date: January 2008
Phase: Phase 2/Phase 3
Study type: Interventional

The aim of this clinical study in adult ALL is to compare by risk category (1) the feasibility of two different CNS prophylaxis regimens and (2) the overall disease-free survival in relation to the achievement of an early MRD negative status and following consolidation with lineage-targeted methotrexate infusions and other disease-specific therapeutic elements, with or without the application of allogeneic or autologous SCT depending on risk class and MRD study results. In this multicentric prospective pilot randomized phase II trial on CNS prophylaxis, all patients receive induction/consolidation therapy incorporating lineage-targeted high-dose methotrexate plus other drugs (with additional imatinib in Ph/BCR-ABL+ ALL), for the achievement of an early negative MRD status. The MRD study supports a risk/MRD-oriented final consolidation phase.

NCT ID: NCT00560794 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)

Start date: January 2008
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether the bispecific T-cell engager (BiTE®) Blinatumomab (MT103) is effective in the treatment of ALL patients with minimal residual disease.

NCT ID: NCT00458523 Completed - Leukemia Clinical Trials

Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission

Start date: December 2006
Phase: Phase 2
Study type: Interventional

RATIONALE: Monoclonal antibodies, such as alemtuzumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. PURPOSE: This phase II trial is studying the side effects and how well alemtuzumab works in treating patients with B-cell chronic lymphocytic leukemia in partial remission or complete remission.

NCT ID: NCT00358072 Completed - Clinical trials for Acute Lymphoblastic Leukemia

Treatment of Adult ALL With an MRD-directed Programme.

Start date: May 2000
Phase: Phase 2
Study type: Interventional

The study aims to optimize the concept of risk-oriented postremission consolidation therapy, by offering (i) standard consolidation-maintenance to patients at lowest risk of relapse as defined by MRD(Minimal Residual Disease) negative status, and (ii) allogeneic stem cell transplantation (related/unrelated donor available) or multicycle high-dose therapy with autologous blood stem cell transplant (no donor) to patients at highest risk of relapse as defined by MRD+ status. The prognostic role of MRD evaluation in unselected patients will be evaluated.

NCT ID: NCT00267085 Completed - Clinical trials for Chronic Myeloid Leukemia

Synthetic Vaccine in Patients With Chronic Myeloid Leukemia and Minimal Residual Disease

Start date: December 2005
Phase: Phase 2
Study type: Interventional

The goal of this clinical research study is to learn if giving 1 of 2 CML (Chronic Myeloid Leukemia) vaccines (CML-VAX B2 or CML-VAX B3) together with imatinib mesylate can decrease or eliminate all evidence of disease in patients who have CML that is in remission after treatment with imatinib mesylate, but who still have small amounts of detectable disease.

NCT ID: NCT00179829 Completed - Cancer Clinical Trials

WT1 for the Detection of Minimal Residual Disease

Start date: February 1999
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.